Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing

March 13, 2024

https://www.globenewswire.com/news-release/2024/03/13/2845857/0/en/Lexeo-Therapeutics-Announces-Closing-of-Oversubscribed-95-0-Million-Equity-Financing.html

NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) — Lexeo Therapeutics, Inc. (Nasdaq:LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer’s disease, today announced the closing of its previously announced private placement. The financing was co-led by Braidwell LP and Adage Capital Partners LP with participation from new and existing investors including RA Capital Management, Surveyor Capital (a Citadel company), Eventide Asset Management, Novo Holdings A/S, Invus, Laurion Capital Management, Longitude Capital, Omega Funds and Woodline Partners LP for total gross proceeds of approximately $95.0 million.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.